Ratnakar N Asolkar1, Ahilya Singh2, Paul R Jensen1, William Aalbersberg2, Brad K Carté2, Klaus-D Feussner2, Ramesh Subramani3, Antonio DiPasquale4, Arnold L Rheingold4, William Fenical1. 1. Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA, 92093-0204, USA. 2. Institute of Applied Sciences, Faculty of Science, Technology and Environment, The University of the South Pacific, Laucala Campus, Private Mail Bag, Suva, Fiji. 3. Department of Biology, College of Engineering, Science & Technology (CEST), School of Science, Dept. of Biology, Fiji National University, Natabua Campus, Lautoka, Fiji. 4. Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA.
Abstract
Six cytotoxic and antimicrobial metabolites of a new bromo-phenazinone class, the marinocyanins A-F (1-6), were isolated together with the known bacterial metabolites 2-bromo-1-hydroxyphenazine (7), lavanducyanin (8, WS-9659A) and its chlorinated analog WS-9659B (9). These metabolites were purified by bioassay-guided fractionation of the extracts of our MAR4 marine actinomycete strains CNS-284 and CNY-960. The structures of the new compounds were determined by detailed spectroscopic methods and marinocyanin A (1) was confirmed by crystallographic methods. The marinocyanins represent the first bromo-phenazinones with an N-isoprenoid substituent in the skeleton. Marinocyanins A-F show strong to weak cytotoxicity against HCT-116 human colon carcinoma and possess modest antimicrobial activities against Staphylococcus aureus and amphotericin-resistant Candida albicans.
Six cytotoxic and antimicrobial metabolites of a new n class="Chemical">bromo-phenazinonen> class, the marinocyanins A-F (1-6), were isolated together with the known bacterial metabolites 2-bromo-1-hydroxyphenazine (7), lavanducyanin (8, WS-9659A) and its chlorinated analog WS-9659B (9). These metabolites were purified by bioassay-guided fractionation of the extracts of our MAR4 marine actinomycete strains CNS-284 and CNY-960. The structures of the new compounds were determined by detailed spectroscopic methods and marinocyanin A (1) was confirmed by crystallographic methods. The marinocyanins represent the first bromo-phenazinones with an N-isoprenoid substituent in the skeleton. Marinocyanins A-F show strong to weak cytotoxicity against HCT-116humancolon carcinoma and possess modest antimicrobial activities against Staphylococcus aureus and amphotericin-resistant Candida albicans.
Authors: Hans-Peter Fiedler; Christina Bruntner; Alan T Bull; Alan C Ward; Michael Goodfellow; Olivier Potterat; Carsten Puder; Gerhard Mihm Journal: Antonie Van Leeuwenhoek Date: 2005-01 Impact factor: 2.271
Authors: O Nakayama; N Shigematsu; A Katayama; S Takase; S Kiyoto; M Hashimoto; M Kohsaka Journal: J Antibiot (Tokyo) Date: 1989-08 Impact factor: 2.649
Authors: Nicholas V Borrero; Fang Bai; Cristian Perez; Benjamin Q Duong; James R Rocca; Shouguang Jin; Robert W Huigens Journal: Org Biomol Chem Date: 2014-02-14 Impact factor: 3.876
Authors: Tamara P Kondratyuk; Eun-Jung Park; Rui Yu; Richard B Van Breemen; Ratnakar N Asolkar; Brian T Murphy; William Fenical; John M Pezzuto Journal: Mar Drugs Date: 2012-02-16 Impact factor: 6.085
Authors: Mamona Nazir; Muhammad Saleem; Muhammad Imran Tousif; Muhammad Aijaz Anwar; Frank Surup; Iftikhar Ali; Daijie Wang; Nilufar Z Mamadalieva; Elham Alshammari; Mohamed L Ashour; Ahmed M Ashour; Ishtiaq Ahmed; Ivan R Green; Hidayat Hussain Journal: Biomolecules Date: 2021-06-29